Current Report Filing (8-k)
July 17 2019 - 3:26PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported)
July 8,
2019
FIRST COLUMBIA DEVELOPMENT CORP.
(Exact name of registrant as specified in its charter)
Nevada
|
333-181259
|
N/A
|
(State or other jurisdiction of
|
(Commission File Number)
|
(IRS Employer
|
incorporation)
|
|
Identification No.)
|
3020 Bridgway, Ste 505, Sausalito, CA
|
94965
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrants telephone number, including area code
415-300-6144
_____________________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
[ ] Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b -2
of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. [ ]
- 2 -
Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Mario Gobbo was appointed as a Director on July 8, 2019.
Mario Gobbo is an independent consultant since 2010 when he was
head of life sciences equity capital markets and M&A for Natixis
Bleichroeder, a boutique investment bank in New York, which he had joined in
2006. He has 35 years of banking and corporate finance experience in healthcare
and energy. His expertise encompasses venture capital and private equity as well
as investment banking and strategic advisory. He is on the board of
Zavarovalnica Triglav, the largest Slovene insurance company spearheading
healthcare insurance in Central Europe and was Chairman of the Board and Chair
of the Audit Committee of Helix BioPharma, a Toronto listed biotech company
developing interesting novel complex biomolecules to combat various cancers.
When with Natixis Bleichroeder, he obtained mandates for several IPOs and
follow-on transactions on NASDAQ, as well as advisory assignments for health
care and medical devices companies. With International Finance Corporation, a
World Bank Group institution dealing with private sector investments, the team
he led completed several highly successful equity and loan investments in
biotech and generic pharmaceutical companies and funds in India, Latin America,
China and Central Europe. From 1993 to 2001, he was with Lazard in London, where
he created and managed their Central and Eastern European operations. As an
executive director, he sat on the Lazard Brothers Board in London. He advised on
M&A, fundraising and privatization efforts for several key firms in the
region, including transactions for the pharmaceutical companies Pliva,
Bosnalijek, Lek and Krka. Prior to Lazard, he worked with Swiss Bank Corporation
International Ltd. in London, where he worked on the IPO of Ares Serono, the
Swiss biotech company, subsequently sold to Merck KgaA. He was also on the
investment committee of AHF, an India focused health care fund, Ocimum
Biosolutions/Genelogic, an Indian contract research organization, and
CellPraxis, a US/Brazilian stem cell research, privately owned firm.
He holds a BA with a major in Organic Chemistry from Harvard
College, a Master of Science in Biochemistry from the University of Colorado and
an MBA, a Master of Business Economics and a PhD (Management) from the Wharton
School of the University of Pennsylvania. And currently resides in Chevy chase,
Maryland.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
First Colombia Development Corp.
/s/ Christopher
Hansen
|
|
Christopher Hansen
|
|
CEO, Principal Executive Officer
|
|
Date: July 17, 2019